Skip to search boxSkip to navigationSkip to main content

Prediction of cervical histologic results using an abbreviated Reid Colposcopic Index during ALTS

  • the ALTS Group
    ,
  • Daron G. Ferris(corresponding author)
    ,
  • Mark S. Litaker
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Objective: The purpose of this study was to determine the accuracy of an abbreviated Reid Colposcopic Index (RCI) to detect cervical intraepithelial neoplasia (CIN) 2 and CIN 3 during the National Cancer Institute (NCI) ASCUS LSIL Triage Study (ALTS). Study design: Colposcopists from 4 ALTS clinical centers indicated an RCI score after colposcopically examining subjects. Colposcopy quality control reviewers also documented an RCI score for the same subjects after assessing their digitized cervical images. Associations of colposcopist and reviewer RCI scores with histologic results were evaluated. Agreement rates between colposcopists and reviewers were calculated for colposcopic impression. Results: Overall RCI score agreement was poor (weighted Kappa = 0.17). The sensitivity, specificity, positive and negative predictive values of a colposcopist's RCI score of >3/6 to detect CIN 3 or worse were 37.3% (95% CI 32.5%-42.3%), 89.7% (88.6%-90.8%), 30.8% (26.7%-35.2%), and 92.1% (91.1%-93.0%), respectively. The 3 colposcopic signs were not individually sensitive in detecting CIN 3. Conclusion: Colposcopists using the RCI in the ALTS trial failed to detect CIN 2/3 at the levels expected.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 704-710 (7 pages)

Journal (Volume, Issue Number)

American journal of obstetrics and gynecology (Volume 194, Issue 3)

Publication milestones

  • Published - 03/2006

Publication status

Published - 03/2006

ISSN

0002-9378

Publication IDs

  • Scopus: 33644692051
  • PubMed: 16522401

Publication metrics

Metrics

Scopus
citations
SciVal
citations
69
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1
SciVal
FWCI
5.69
SciVal
Author count
2
SciVal
Paper percentile
91
SciVal
Top percentile
10

PlumX, opens in new tab

Citation count
87
Captures
27

Funding Details

Supported by the National Cancer Institute, National Institutes of Health Department of Health and Human Services contracts CN-55153, CN-55154, CN-55155, CN-55156, CN-55157, CN-55158, CN-55159, and CN-55105. Some of the equipment and supplies used in this study were donated or provided at reduced cost by Digene Corporation, Gaithersburg, MD; Cytyc Corporation, Boxborough, MA; National Testing Laboratories, Fenton, MO; Denvu, Tucson, AZ; TriPath Imaging, Inc, Burlington, NC; and Roche Molecular Systems, Inc, Alameda, CA.
FundersFunding numbers
NCI
-
National Institutes of Health, Department of Health and Human Services
CN-55158, CN-55159, CN-55156, CN-55157, CN-55105, CN-55154, CN-55155, CN-55153